Tesamorelin

Also known as: Egrifta

FDA-approved GHRH analog for HIV-associated lipodystrophy; used off-label for fat loss.

Typical dose
1.4 mg – 2 mg
Frequency
once daily
Route
Subcutaneous
Half-life
30 minutes
Routes
Subcutaneous
Status
FDA-approved (HIV lipodystrophy)
Track your Tesamorelin protocol in Vial →

Benefits

Dosing

A common research range for Tesamorelin is 1.4 mg to 2 mg once daily. EGRIFTA SV: 1.4mg/day; original formulation 2mg/day. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.

Reconstitution

A typical reconstitution for Tesamorelin is 2 mg of peptide in 2 mL of bacteriostatic water, giving roughly 1 mg per mL. Vial's built-in calculator works out the exact syringe draw for any vial size and dose.

Half-life

Tesamorelin has an approximate half-life of 30 minutes. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.

Storage

2-8°C post-reconstitution.

Reported side effects

Contraindications

Track Tesamorelin with Vial

Vial logs every Tesamorelin dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →

This page is for educational and harm-reduction purposes only. Tesamorelin is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.